World Cancer Day

by | Feb 4, 2021 | Cancer, FDA, Healthcare, Medicine, Pharmaceuticals

World Cancer Day, established by the Union for International Cancer Control (UICC) in 2000, is observed every year on February 4th. Over 10 million people die each year from cancer, more than HIV/AIDS, malaria, and tuberculosis combined.1 This makes cancer a leading cause of death with a global impact; cancer is not specific to any one geographic region or any one demographic. Cancer can affect anyone of any age, but we are moving towards extraordinary medical breakthroughs in the fight against cancer.

Breakthrough technology like proton/photon therapy, coupled with advances in surgical interventions and chemotherapy, are leading the charge in global cancer treatment. These treatments are allowing people to live longer with a higher quality of life. Despite this, access to early detection healthcare continues to be an obstacle. The UICC estimates that more than one-third of cancer cases can be prevented, and another third are curable if detected early. The UICC states that prevention and early detection strategies could save up to 3.7 million lives annually.2

Many nations are tackling cancer head-on, in the United States the FDA Oncology Center of Excellence was established with the mission to “…create a unified and collaborative scientific environment to advance the development and regulation of oncology products for patients with cancer.”3 This center created the Patient-Focused Drug Development (PFDD) program, led by some of the world’s leading names in Oncology, to actively improve the way cancer-specific drug treatments were developed, regulated, and distributed to patients. The PFDD’s key focus areas are engaging with patients, promoting research on patient experience, and improving regulatory policy by leveraging science-based recommendations.4

The effects cancer has on patients and their families can not be overstated. EMMA International has worked hand-in-hand with several organizations across the life-science industry to ensure their ground-breaking cancer treatment products were compliant with all applicable quality and regulatory requirements. Through this, we have also had the privilege of being a part of a global community of healthcare providers working every day to cure and prevent cancer.

EMMA International is available 24/7 to support your quality and regulatory needs. Contact us at 248-987-4497 or email to get in touch with our team of experts today.

1CDC (Feb 2021) Cancer Resource Center retrieved on 02/02/21 from:

2UICC (Feb 2021) Why Cancer? Retrieved on 02/02/21 from:

3FDA (n.d.) Oncology Center of Excellence retrieved on 02/02/21 from:

4FDA (Nov 2020) Patient-Focused Drug Development retrieved on 02/02/21 from:


Madison Wheeler

Madison Wheeler

Director of Technical Operations - Ms. Wheeler serves as EMMA International’s Director of Technical Operations. She has experience in technical writing, nonconforming product management, issue evaluations, and implementing corrective and preventative actions in the pharmaceuticals and medical device industries. She has experience cross-functionally between R&D, lean manufacturing operations, and RA compliance. Ms. Wheeler also has academic and work experience with human health-risk engineering controls, physiological biophysics, and clinical research. Ms. Wheeler holds a Bachelor of Science in Biosystems Engineering with a concentration in Biomedical Engineering from Michigan State University. She is also a Certified Quality Auditor (CQA), and is currently pursuing her M.S. in Quality Management.

More Resources

Abbreviated 510k submission

Abbreviated 510k submission

There are three types of 510K, Premarket Notifications, which can be submitted to the Food and Drug Administration (FDA) traditional, abbreviated, and special. Abbreviated and Special 510K submissions can be utilized when the submissions meet the certain factors presented by the FDA. When submitting an abbreviated 510K the submission must include the elements that are identified in 21CFR 807.87 for the information required in a premarket notification submission.
Is your product a medical device?

Is your product a medical device?

Many marketed products are classified as medical devices and you would not even know it. Medical devices range from latex gloves and tongue depressors to respirators and heart valves. To determine if the product is considered a medical device by the Food and Drug Administration (FDA) you will need to analyze if your product meets the definition of a medical device per the Food, Drug, and Cosmetic Act1.
Sterilization of Medical Devices

Sterilization of Medical Devices

There are many ways to sterilize medical devices before use in the industry. The common methods utilized are steam, radiation, dry heat, ethylene oxide, and vaporized hydrogen peroxide. There are two methods of sterilization for medical devices recognized by the Food and Drug Administration (FDA), established and novel.

Ready to learn more about working with us?

Pin It on Pinterest

Share This